MedTrace Logo

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

NCT07057765 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-07-10

No results posted yet for this study

Summary

This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.

Conditions

  • DLBCL - Diffuse Large B Cell Lymphoma
  • Markers of Inflammation

Interventions

DRUG

Observational Assessment of Standard R-CHOP Treatment

Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Mahmoud M Ellithy, MD · Faculty of Medicine, Ain Shams University

  • Shaimaa A Pessar, MD · Faculty of Medicine, Ain Shams University

  • Reham M Faheim, MD · Faculty of Medicine, Ain Shams University

  • Doaa A Mohamed, MD · Faculty of Medicine, Ain Shams University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2026-05-31
Completion
2026-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07057765 on ClinicalTrials.gov